ANI Pharmaceuticals Q3 net income rises 32% to $35.15 million

By Public Technologies11:54 (UTC), 5 November 2026 Updated

ANI Pharmaceuticals’ third-quarter 2026 GAAP net income available to common shareholders rose 34% year-over-year to $35.15 million.
Total net revenues climbed 28% year-over-year to $290.78 million, while Cortrophin Gel net revenues increased 36% to $138.66 million.
Specialty pharmacy capacity constraints slowed Cortrophin Gel revenue conversion; expansion of the network and patient support capabilities is underway.
A proposed acquisition of Egetis Therapeutics for approximately $560 million would add rare disease therapy EMCITATE.
Full-year 2026 Cortrophin Gel net revenues guidance fell to $480 million–$500 million from $520 million–$540 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050651PRIMZONEFULLFEED9871039) on November 05, 2026, and is solely responsible for the information contained therein.